New Delhi:The Supreme Court will on Monday hear fresh PIL seeking directions under the Disaster Management Act (DMA) to prevent the sale of counterfeit COVID-19 vaccines.
The PIL was filed by the lawyer Vishal Tiwari.
A three-judge bench of the apex court, headed by Justice Dr Dhananjaya Y Chandrahud and also comprising Justices L Nageswara Rao and Shripathi Ravindra Bhat will hear on May 31 the fresh petition filed by Tiwari with his "concrete facts", in the case.
A three-judge bench of the top court headed by the then CJI Sharad Arvind Bobde had on February 11, 2021, refused to entertain the petition of Tiwari and asked him to file a fresh one, with "concrete facts" in the matter.
Read:Johnson & Johnson ties up with Biological E to manufacture one-shot Covid-19 vaccine
"We understand your motivation. But you (Tiwari) file a fresh case with concrete facts. We cannot issue general directions. We are not the legislature", the three-judge bench of the top court, led by the CJI (retired now) Bobde had said.
The PIL seeks a direction to the Union of India (UOI) and others, to issue strict guidelines and regulations under the DMA by constituting a special committee to prevent the chances of fake and counterfeit COVID vaccine selling/circulating by any organization, company and online apps.
The petitioner sought appropriate directions that the respondents, including the Centre, be directed to run the awareness programme for the safety of the citizens against the danger of counterfeit vaccination of coronavirus.
Tiwari, in his petition, sought a direction that the respondents be directed to enact a strict law against the criminal act committed by selling or circulating the counterfeit vaccine by any organization or individual.
The petitioner noted that the COVID pandemic took the entire world into its captivity.
The petition said all countries have already started research for its cure and after several months of a research programme, some countries are successful in inventing the vaccine against the infection of coronavirus.
It said United Kingdom gained the first position in launching the anti-COVID vaccine programme for its citizens and authorized Pfizer for anti-COVID vaccination.